The Coeliac Guideline: When a Biopsy Isn't Needed

An endoscopy slot is an expensive way to confirm what a blood test has already stated. For twelve years, British guidance required exactly that: every adult coeliac diagnosis passed through the camera, whatever the antibody level. The 2026 British Society of Gastroenterology guideline, published in Gut and still settling into clinic workflows this autumn, removes that requirement for a carefully bounded group of patients. It also does something less quotable and more useful. It puts numbers and timelines around the parts of coeliac disease that used to float, namely the ambiguous presentation, the person who does everything right and stays unwell, and the long stretch of years after the diagnosis letter arrives.

The No-Biopsy Pathway Has Narrow Doors

The pathway is optional and deliberately unglamorous. According to the published guideline, an adult with symptoms of coeliac disease, assessed in secondary care and eating gluten at the time of testing, can be diagnosed without duodenal biopsy when their IgA tissue transglutaminase titre sits at least ten times the assay's upper limit of normal. The decision requires a conversation with the patient, and endoscopy stays the right call where red-flag symptoms, a suspected alternative diagnosis or another reason for upper gastrointestinal evaluation exists.

Two boundary lines matter as much as the tenfold figure. The guidance does not extend the pathway to primary care, to screening populations or to asymptomatic people, because the predictive value of a very high titre falls when it's applied to a group where the disease is rare. It also asks laboratories to apply assay-specific thresholds rather than one universal number, since antibody tests from different manufacturers don't count on the same scale. That last detail is the sort of thing that decides whether a pathway works in practice or quietly mislabels people.

Loading Diagram...(Hard refresh if it doesn't appear)

Why the Tenfold Cut-Off Carries the Whole Argument

The logic behind the threshold is pre-test probability, and it's the part clinicians and patients most often skip. A test's accuracy isn't a fixed property of the test. It shifts with the population in front of you. In a gastroenterology clinic where someone arrives with diarrhoea, weight loss and iron deficiency, a titre ten times normal is close to decisive. The same number in an asymptomatic person picked up by a workplace health screen proves considerably less, which is why the guideline confines the option to symptomatic adults already referred onward.

Read that way, the no-biopsy pathway looks less like a loosening of standards and more like a routing decision about scarce endoscopic capacity. Fifteen graded recommendations back the document, and the diagnostic section spends real space on how biopsies should be taken when they are needed: at least four from the second part of the duodenum, two from the bulb, single-bite technique wherever possible. A guideline that wanted to abandon histology wouldn't invest that much ink in sampling.

The risk sits with the mislabel. A coeliac diagnosis is for life, and it reshapes every meal, every work lunch, every family gathering. Getting it wrong in either direction costs years. The safeguard in the document is the shared decision-making step, which only works if the person in the room hears the word optional and understands that the biopsy remains available if they want the certainty.

Follow-Up Is Where the Guideline Changes Behaviour

Every patient diagnosed with coeliac disease should now have structured follow-up for up to two years, with attention concentrated on symptom response, dietary adherence, nutritional status and early detection of complications. The update replaces a flatter model with a risk-based one. The 2014 document centred on the diagnostic rule and left the years afterwards largely to local habit; the new version treats the first 24 months as the window where the outcome is decided and the years beyond as conditional.

Where a clinic reviews at diagnosis, three months, six months, one year and two years, that's five contacts inside two years. Under a plain annual review model, a patient would need two decades of appointments to accumulate the same number of touchpoints. The math explains the front-loading. The gluten-free diet is hardest in month one, the learning curve is steepest before the first anniversary, and symptoms and antibody levels respond on a timescale that fits inside that window.

Beyond two years, stable patients can move to patient-initiated follow-up, meaning they contact the service when something changes instead of attending on a calendar. Conventional follow-up remains for people with persistent symptoms, poor adherence, ongoing villous atrophy or complications. That split is the most defensible thing in the document. An annual appointment that produces no decision, no test change and no change in symptoms is administration rather than care, and it takes clinic time the newly diagnosed actually need.

Complex Presentations Finally Have Working Definitions

Coeliac disease has always had an awkward middle. People with positive antibodies and normal biopsies, people with damaged villi and negative antibodies, people whose changes sit only in the duodenal bulb. For years these patients were described in clinic letters with hedged language and managed by improvisation. The 2026 guideline gives each category a definition, a monitoring plan and, where relevant, a route to treatment.

The refractory section is the most clinically useful part. Types 1 and 2 now have a sequence covering the confirmation steps that must happen before the label is applied, including verifying that gluten exposure is genuinely absent, then the treatment route once it is. Refractory disease is rare, which is exactly why it gets mishandled. A general gastroenterologist may see a handful of cases in a career, and a clear sequence removes some of the guesswork.

What to Bring to the Appointment

If you're the patient, the guideline changes what you should ask for. Ask for the numeric titre rather than the word positive, and ask for your total IgA, since IgA deficiency makes the standard antibody test unreliable and the guideline advises screening for it alongside the coeliac serology. Four things are worth writing down before the appointment:

• The titre as a multiple of the assay's upper limit of normal, not just as positive or negative
• Whether total IgA was measured alongside the coeliac serology
• Whether the plan includes a dietitian with coeliac expertise, and when that happens
• The scheduled review points inside the first two years, and what triggers a return after that

The dietitian question is the one most likely to be answered badly. Specialist dietetic input is where adherence gets built, and the guideline leans on it, yet access varies enormously between trusts and between health systems. A no-biopsy pathway that shortens the diagnostic queue without adding capacity at the dietetic end has moved the bottleneck rather than removed it.

The biopsy debate is the headline and the least consequential part of this document. A camera is a procedure with a queue attached, and shortening that queue for a narrow, well-defined group is sensible housekeeping. The parts that will determine whether people with coeliac disease are better off in 2030 carry no drama at all: a follow-up model that spends its attention where the disease is unstable, definitions that end a decade of hedging, and a dietitian appointment that either exists or doesn't. Until the capacity matches the standard, the tenfold threshold will shorten waiting lists more reliably than it will improve lives.